OQROGet OQRO Pro
Politician trade (House)

Johnson & Johnson (JNJ)Rep. Richard Dean Dr McCormick (GA06) disclosed a purchase $1K–$15K

Rep. Richard Dean Dr McCormick (GA06) disclosed a purchase of Johnson & Johnson in the $1K–$15K range.

$1,001–$15,000
Reported range · official band, not an exact amount
34 days
Disclosure lag
Traded
Nov 5, 2025
Disclosed
Dec 9, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Mar 15, 2023CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  2. Oct 29, 2024CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  3. Mar 19, 2025CongressDisclosed sale of JNJ — reported range $15,001 - $50,000
  4. Aug 4, 2025Congress · 1 personMembers of Congress: 2 purchases
  5. Aug 14, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  6. Aug 19, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  7. Sep 8, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 8, 2025, Johnson & Johnson (the Company) announced that John Morikis was elected to the Board of Directors. The Board has determined that Mr. Morikis satisfies the applicable independence requirements of the NYSE Listed Company Manual.”
  8. Sep 23, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  9. Oct 9, 2025Federal contract · $19K obligatedDepartment of Veterans Affairs awarded Johnson & Johnson: $19K obligated to date
  10. Oct 10, 2025Congress · 1 personMembers of Congress: 2 sales
  11. Oct 14, 2025Company filing · Form 8-K · Results, Other newsReported its results, and reported other company news
  12. Oct 16, 2025Federal contract · $384K obligatedDepartment of Defense awarded Johnson & Johnson: $384K obligated to date
  13. Oct 17, 2025InsiderOfficer sold ~$4.19M of JNJ shares in the open market
  14. Oct 30, 2025Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  15. Oct 31, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  16. Nov 5, 2025 · this disclosureCongressDisclosed purchase of JNJ — reported range $1,001 - $15,000

What came next

  1. Nov 6, 2025Insider10% owner sold ~$534K of JNJ shares in the open market
  2. Nov 7, 2025Insider10% owner sold ~$2K of JNJ shares in the open market
  3. Nov 12, 2025Insider10% owner sold ~$10K of JNJ shares in the open market
  4. Nov 13, 2025CongressDisclosed partial sale of JNJ — reported range $1,001 - $15,000
  5. Nov 20, 2025CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  6. Nov 21, 2025Insider10% owner sold ~$5K of JNJ shares in the open market
  7. Nov 24, 2025Insider10% owner sold ~$22K of JNJ shares in the open market
  8. Nov 25, 2025Insider10% owner sold ~$160K of JNJ shares in the open market
  9. Nov 26, 2025Insider · 2 peopleInsiders: 1 purchase (~$258K), 2 sales (~$127K)
  10. Dec 9, 2025CongressDisclosed purchase of JNJ — reported range $1,001 - $15,000
  11. Dec 10, 2025Federal contract · $8K obligatedDepartment of Defense awarded Johnson & Johnson: $7.7K obligated to date
  12. Dec 18, 2025CongressDisclosed sale of JNJ — reported range $1,001 - $15,000
  13. Jan 21, 2026Company filing · Form 8-K · ResultsReported its results
  14. Jan 23, 2026CongressDisclosed partial sale of JNJ — reported range $15,001 - $50,000
  15. Jan 26, 2026Insider · 1 personInsiders: 2 sales (~$22.1M)
  16. Jan 27, 2026FDAFDA drug approval: Darzalex Faspro
  17. Jan 27, 2026FDARecall: Impella RP. Product Code: 0046-0011.
  18. Jan 27, 2026FDARecall: Impella RP Flex with SmartAssist. Product Code: 1000323.
  19. Feb 5, 20265% stakeThe Vanguard Group reported a passive stake (13G) of 10.1%
  20. Feb 6, 2026FDAFDA device clearance: MONOCRYL™ Plus Antibacterial Poliglecaprone – 25 (Monofilament), Sterile Synthetic Absorbable Surgical Suture
View the official recordHouse Clerk periodic transaction report

How to read House Clerk periodic transaction report

The STOCK Act is a 2012 US law that requires members of Congress, and some senior staff, to publicly report their stock trades, and those of their spouse and dependent children, within 45 days.

Full guide: What is the STOCK Act?

What else is on file for Johnson & Johnson

For Johnson & Johnson, OQRO holds 15 insider filings (SEC Form 4 or Form 144), 8 Congress trade reports, 167 fund holdings reports (13F) and 5 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its JNJ page.

Other recent filings by Rep. Richard Dean Dr McCormick (GA06)

The full history of Rep. Richard Dean Dr McCormick (GA06) is on the profile page.

How this filing works

Other disclosures at Johnson & Johnson

Everything OQRO holds on this company is on its JNJ page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data